Proton pump inhibitors and hospital discharge rates for gastrointestinal events in italy: A national ecological study

Clinical Therapeutics

Volumn 29, Issue 4, 2007, Pages 751-758

  Russo, Pierluigi ^a   Brutti, Chiara ^a  

^a ITALIAN MEDICINES AGENCY   (Italy)

Author keywords

ecological study; expenditure; hospital admissions; pharmaco utilization; protein pump inhibitors

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; PROSTAGLANDIN; PROTON PUMP INHIBITOR;

ARTICLE; CALCULATION; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG USE; DRUG UTILIZATION; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; ITALY; NATIONAL HEALTH SERVICE; PEPTIC ULCER; REIMBURSEMENT; STATISTICAL SIGNIFICANCE;

ANALYSIS OF VARIANCE; BIAS (EPIDEMIOLOGY); DATA COLLECTION; DRUG UTILIZATION REVIEW; ECONOMICS, PHARMACEUTICAL; HEALTH CARE SURVEYS; HOSPITALIZATION; HOSPITALS, PUBLIC; HUMANS; ITALY; NATIONAL HEALTH PROGRAMS; PATIENT DISCHARGE; PEPTIC ULCER; PROTON PUMPS;

EID: 34347382187     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.04.008     Document Type: Article

References (23)

1. US Dept of Health and Human Services, National Center for Health Statistics, and Centers for Disease Control and Prevention. National Hospital Discharge Survey: 2001 Annual summary with detailed diagnosis and procedure. National Vital Statistics Reports 56 (2004) 1-207
2. US Dept of Health and Human Services, National Center for Health Statistics, and Centers for Disease Control and Prevention. Deaths: Final data for 2002. National Vital Statistics Reports 53 (2004) 1-116
3. Summer. UK Office for National Statistics. Table 6.3 England and Wales-Deaths: Selected causes (International Classification) and sex. Health Statistics Quarterly 14 (2002) 62-63
4. CD002094. Leontiadis G.I., McIntyre L., Sharma V.K., and Howden C.W. Proton pump inhibitor treatment for acute peptic ulcer bleeding. Cochrane Database Syst Rev. (2004)
5. Leontiadis G.I., Sharma V.K., and Howden C.W. Systematic review and meta-analysis of proton pump inhibitor therapy in peptic ulcer bleeding. BMJ 330 (2005) 568
6. CD002296. Rostom A., Dube C., Wells G., et al. Prevention of NSAIDinduced gastroduodenal ulcers. Cochrane Database Syst Rev. (2002)
7. Pillars P.I., Kubler P.A., Radford J.M., and Overland V. Concordance between use of proton pump inhibitors and prescribing guidelines. Med J Aust. 172 (2000) 16-18
8. Arasaradnam R.P., Woodward T., Parrack L., et al. Audit of proton pump inhibitor (PPI) prescribing: Are NICE guidelines being followed?. Clin Med. 3 (2003) 387-388
9. Bashford J.N., Norwood J., and Chapman S.R. Why are patients prescribed proton pump inhibitors? Retrospective analysis of link between morbidity and prescribing in the General Practice Research Database. BMJ 317 (1998) 452-456
10. Ministero della Sanità, and Dipartimento per la Valutazione dei Medicinali e la Farm acovigilanza. Elenco delle note aggiornate e revisionate dalla Commissione Unica del Farmaco. Bollettino di In formazione sui Farmaci 2 (1998) 2-59
11. Ministero della Sanità, and Dipartimento per la Valutazione dei Medicinali e la Farmacovigilanza. Le nuove note CUF. Bollettino di Informazione sui Farmaci (2000) 54-96
12. The Italian Medicines Agency (AIFA). The use of medicines in Italy-National Report-Year 2005 (2006), Pensiero Scientifico Editore, Rome, Italy
13. US Dept of Health and Human Services, Centers for Disease Control and Prevention, and National Center for Health Statistics (NCHS). International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9CM) (2003), NCHS, Hyattsville, Md
14. Cattaruzzi C., Troncon M.G., Agostinis L., and Garcia Rodriguez L.A. Positive predictive value of ICD-9th codes for upper gastrointestinal bleeding and perforation in the Sistema Informativo Sanitario Regionale clatabase. J Clin Epidemiol 52 (1999) 499-502
15. Italian Ministry of Health. Update of tariffs for hospital assistance services allocated according to the National Health Service and relative tariffs (June 30, 1997), Ministry Decree
16. Available at:. World Health Organization [WHO]. About the Anatomical Therapeutic Chemical/Defined Daily Dose sys tem [WHO Collaborating Centre Web site]. Accessed on March 30 (2007). http://www.whocc.no/atcddd/atcsystem.html
17. [published correction appears in Gut. 2003; 52:458]. Higham J., Kang J.Y., and Majeed A. Recent trends in admissions and mortality due to peptic ulcer in England: Increasing frequency of haemorrhage among older subjects. Gut 50 (2002) 460-464
18. In: Bernstein A.B., Hing E., Moss A.J., et al. (Eds). Health Care in America: Trends in Utilization (2003), Centers for Disease Control and Prevention, National Center for Health Statistics, Hyattsville, Md
19. Gasparini R., Lucioni C., Lai P., et al. Cost-benefit evaluation of influenza vaccination in the elderly in the Italian region of Liguria. Vaccine 20 Suppl 5 (2002) B50-B54
20. Degli Esposti L., Di Martino M., Saragoni S., et al. Cost benefit of lipid-lowering drugs for primary and secondary prevention of cardiovascular disease. Expert Rev Pharmacoecon Outcomes Res. 5 (2005) 1-11
21. McManus P., Marley J., Birkett D.J., and Lindner J. Compliance with restrictions on the subsidized use of pro ton pump inhibitors in Australia. Br J Clin Pharmacol 46 (1998) 409-411
22. The Royal Pharmaceutical Society of Great Britain. NICE suggests 15 percent of PPI use could be stopped. The Pharmaceutical Journal 265 (2000) 82
23. Vakil N.B., Traxler B., and Levine D. Dysphagia in patients with erosive esophagitis: Prevalence, severity, and response to proton pump inhibitor treatment. Clin Gastroenterol Hepatol. 2 (2004) 665-668